Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell February 24, 2026
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy February 9, 2026
ALPS Global Holding Berhad Named Official Contributor to Malaysia’s National Vaccine Prioritisation Framework – MyPRICISE May 27, 2025
